• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cyclerion Therapeutics, Inc. - Common Stock (NQ:CYCN)

    1.380 +0.030 (+2.21%)
    Streaming Delayed Price Updated: 10:28 AM EST, Jan 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Cyclerion Therapeutics, Inc. - Common Stock

    News headline image
    FOCUSfactor® Beverage Emerges as a Growth Catalyst for Synergy CHC Corp. (NASDAQ: SNYR) – Alongside CYCN, ALMS, EVTV, RDZN See Why
    Via AB Newswire
    News headline image
    Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion’s sGC Stimulator Portfolio Generates Revenues to Enable Company Growth
    Cyclerion Has Renegotiated Praliciguat License Agreement to Obtain Upfront and Near-Term Payments as well as Entered into a License Option Agreement for Olinciguat 
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Regina Graul, Ph.D., Promoted to Chief Executive Officer
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Appoints Regina Graul, Ph.D., as President
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Announces Reverse Stock Split
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Announces Definitive Agreement for Zagociguat and CY3018
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Reports Corporate Update and Full Year 2022 Financial Results
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
    Renowned neuroscience leader to further long-term clinical research strategy and external collaborations 
    From Cyclerion Therapeutics, Inc.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.